A man from Florida has filed a new Xarelto injury lawsuit against Janssen Pharmaceuticals (a division of Johnson & Johnson, which is the U.S. marketing partner of Xarelto) and Bayer A.G. which is the German pharmaceutical giant that manufactures the medication. As part of this lawsuit, he is claiming negligent…
A recent article from Medpage Today looks at new uses being proposed for a class of medications know as new oral anticoagulants (NOACs). This is a fairly new class of medications that includes Xarelto, Eliquis, Pradaxa, and Savaysa. These medications were designed primary to treat patients who suffer from a…
Janssen, which is a division of pharmaceutical giant Johnson & Johnson, is the U.S. marketing partner of Bayer, the German drugmaker that manufactures Xarelto, and has released a report that its new oral anticoagulant (NOAC) is superior to Warfarin (Coumadin) in reducing the risk of ischemic stroke, according to a…
A recent feature from CBS News examined whether Johnson & Johnson and Bayer, the makers of Xarelto, knowingly withheld certain important data for a letter to be published in the New England Journal of Medicine. The specific claim made by lawyers for Xarelto plaintiffs in the multi-district litigation (MDL) class action…
There is a good chance that the millions of people watching this year’s Super Bowl will see a commercial for Xarelto. Xarelto, with a generic name rivaroxaban, is making hundreds of millions of dollars for Beyer and Janssen (a wholly owned Johnson & Johnson subsidiary), and these companies will take…
Xarelto has come under a lot of fire lately, as thousands of people have developed a deadly internal bleeding disorder after taking the anticoagulant, and more than 60 people have died. The basis of these claims are that the makers of Xarelto, Bayer and Janssen (a division of Johnson &…
With the regular NFL season coming to close and playoffs heating up, there will be more people watching football than at any other point in the season. This will, of course, culminate with Super Bowl 50. During the Super Bowl, many will tune in for the big game and others…
Xarelto is a member of class of drugs known as New Oral Anticoagulants (NOACs). It is an alternative to traditional blood thinners such a Warfarin (Coumadin), which is often prescribed to patients who suffer from a serious medical condition known as atrial fibrillation (Afib). Afib is a medical condition classified…
Xarelto, Pradaxa, and Eliquis are three of four New Oral Anticoagulants (NOACs) that are all fighting with each other and the makers of Warfarin (Coumadin) to become the market leader for medications used for the prevention of serious blood clotting disorders in patients who suffer from a medical condition known…
For several years, Pradaxa, Elliquis, and Xarelto have had the market cornered on sales of New Oral Anticoagulants (NOACs) as treatment for patients who suffer from a serious medical condition known as atrial fibrillation (Afib). NOACs are an entirely new class of drugs designed to replace conventional blood thinners, such…